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Abstract
Introduction: Environmental exposures, including smoking, hormone-related factors, and metabolic factors, have
been implicated in the etiology of rheumatoid arthritis (RA). A previous study has indicated that blood lipid levels
may influence the development of RA. The objective of this study was to investigate the impact of serum total
cholesterol and triglycerides on the risk of RA in a prospective study.
Methods: Among participants in a large population-based health survey (n = 33,346), individuals who subsequently
developed RA were identified by linkage to four different registers and a structured review of the medical records.
In a nested case-control study, with controls, matched for age, sex, and year of inclusion, from the health survey
database, the relation between serum lipids (levels of total cholesterol and triglycerides) and future RA
development was examined.
Results: In total, 290 individuals (151 men and 139 women) whose RA was diagnosed a median of 12 years
(range of 1–28) after inclusion in the health survey were compared with 1160 controls. Women with a diagnosis of
RA during the follow-up had higher total cholesterol levels at baseline compared with controls: odds ratio (OR) 1.54
per standard deviation; 95 % confidence interval (CI) 1.22–1.94. This association remained statistically significant in
multivariate models adjusted for smoking and a history of early menopause and in analyses stratified by
rheumatoid factor status and time to RA diagnosis. Total cholesterol had no significant impact on the risk of RA in
men (OR 1.03; 95 % CI 0.83–1.26). Triglycerides did not predict RA in men or women.
Conclusions: A high total cholesterol was a risk factor for RA in women but not in men. This suggests that
sex-specific exposures modify the impact of lipids on the risk of RA. Hormone-related metabolic pathways may
contribute to RA development.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease of multifactorial etiology. Genetics [1] as well as en-
vironmental factors [2] have been implicated. Smoking is
an established predictor of RA [3], and smoking and low
socioeconomic status, as reflected by current occupation
[4] or level of formal education [5], have been shown to
have independent effects on disease development. Overall,
women have a two- to three-fold higher incidence of
RA than men [6]. We have previously demonstrated
that women with early menopause (at age 45 or earlier)
had an increased risk of RA compared with those with
normal/late menopause in models adjusted for smok-
ing, level of education, and length of breast-feeding,
suggesting that hormone-related factors play a part in
the pathogenesis [7].
Metabolic factors may also be important in this
context. Recently, it has been suggested that obesity may
influence both RA onset and disease severity [8]. Inter-
estingly, the effect of obesity may be different in men
and women, and findings indicate a reduced risk of RA
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in obese men [9, 10] and a positive association in
women, in particular with obesity at a young age [11].
In a previous study of blood donors who subse-
quently developed RA and matched controls, average
serum levels of total cholesterol (TC) and triglycerides
(TGs) were higher in pre-RA cases than in controls
[12]. This contrasts with studies of patients with estab-
lished RA, in which lipid levels tend to be lower than
in the general population, in particular in those with
active, uncontrolled inflammation [13]. Furthermore,
treatment with potent biologic anti-rheumatic drugs for
severe, refractory RA has been associated with an
increase in lipid levels, although the atherogenic
index—ratio of low-density lipoprotein (LDL) choles-
terol to high-density lipoprotein (HDL) cholesterol—
appears to be unchanged in most cases [14, 15]. These
patterns are of particular interest because of the in-
creased risk of cardiovascular disease (CVD) in patients
with RA compared with the general population [16],
and data from some studies suggesting a “lipid paradox”
in established RA, in which low TC and TG levels,
probably related to active inflammation, are associated
with CVD events [17].
The purpose of this study was to examine the effect of
serum TC and TG levels on the risk of RA in a pro-
spective study of men and women who were included in
a large population-based health survey. To the best of
our knowledge, this is the first prospective study to in-
vestigate this issue in women and men separately.
Methods
Source population
This nested case-control study used information from
the Malmö Preventive Medicine Program (MPMP), a
population-based health survey performed in Malmö,
Sweden (current population: 300,000; during the screen-
ing period: approximately 235,000) in 1974–1992. The
MPMP included a total of 33,346 individuals: 22,444
males born between 1921 and 1949 and 10,902 females
born between 1925 and 1938. Details on the recruitment
are described elsewhere [18]. The overall response rate
was 71 %. During the first half of the period (1974–82),
mostly men were invited, and mostly females during the
second half (1982–92). The mean ages at screening were
49 years in women and 44 years in men. The vast major-
ity of participants were Caucasians of Scandinavian
origin.
Exposure information
Blood samples were obtained in the morning, between 8
and 10 a.m., after an overnight fast. Serum TC and serum
TG levels were immediately assessed by using fresh sam-
ples by enzymatic methods in routine use at the local hos-
pital laboratory. The erythrocyte sedimentation rate (ESR)
was measured at screening in accordance with the stand-
ard Westergren method. Height and weight were mea-
sured in light indoor clothing. Height was measured to
the nearest centimeter, and weight was recorded at inter-
vals of 0.1 kg. Body mass index (BMI) was calculated as
weight (in kilograms) divided by height (in square meters).
Every participant filled out a self-administered ques-
tionnaire on medical and personal history, including
smoking. For women who participated in April 1983 or
later, the questionnaire included a series of questions on
age at menopause. Similar to previous studies [7, 19],
those with self-reported cessation of menstruations at
age 45 or earlier were classified as having had early
menopause and were compared with those with normal/
late menopause (after 45 years of age). Women who
were younger than 45 years at inclusion were excluded
from analyses that included this parameter.
Data on self-reported overall health and self-reported
cancer, diabetes, and cardiovascular disease (the latter
classified as self-report of either hospitalization for
stroke, physician diagnosis of angina pectoris or current
use of heart medication) at baseline were extracted from
the self-administered questionnaire. Data on socioeco-
nomic status were derived from self-reported job titles
in the Swedish national censuses, as previously described
[4]. Briefly, occupations were coded and converted into
standardized social class categories, and subjects were
classified as “blue-collar workers” (manual workers,
both skilled and unskilled), “white collar workers”
(non-manual employees and self-employed profes-
sionals), and “others” [20].
Cases and controls
As previously described [4], individuals who developed
RA after inclusion in the MPMP and up to 31 December
2004 were identified by linking the MPMP databases to a
community-based RA register [21, 22], the local out-
patient clinic administrative register for Malmö University
Hospital, the National Hospital Discharge Register [23],
and the National Cause of Death Register [24]. In a struc-
tured review of all medical records, possible cases were
validated and classified according to the 1987 American
College of Rheumatology criteria for RA [25]. Only cases
with a first documented diagnosis at least 1 year after in-
clusion in the MPMP were included. The index date was
defined as the date of first diagnosis of RA in the index
case. Four controls for each validated case, who were
matched for sex, year of birth, and year of screening and
who were alive, living in Sweden, and free of RA at the
index date, were selected from the MPMP cohort. Vital
status and information on emigration were retrieved
from the national census, and controls who were not
alive or living in Sweden through the index date were
excluded.
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Data on rheumatoid factor (RF) tests were retrieved
from the two clinical immunology laboratories in the
area. Patients with at least one positive test for RF were
classified as RF-positive, whereas those tested who had
only negative RF tests were classified as RF-negative.
Statistics
The impact of baseline TC and TGs on the risk of RA was
examined in bivariate conditional logistic regression ana-
lysis. Each case and the corresponding controls were given
a group number, which was entered into the logistic re-
gression models as a categorical variable. Odds ratios
(ORs) per standard deviation (SD) of TC were calculated
in men and women separately. To assess potential effect
modification, the slopes for the estimates in men and
women were compared, assuming a normal distribution.
The impact of TC and TGs on the risk of RA was also
assessed by entering the quartile of each of these potential
predictors as a categorical variable in conditional logistic
regression models in men and women separately. The sec-
ond quartile, rather than the first, was used as the reference
in these analyses, as low lipid values may reflect underlying
inflammatory or catabolic conditions [26, 27]. Since TGs
did not have a normal distribution, this was analysed only
as a categorical variable and not as a continuous variable.
The impact of potential confounders on the risk of RA
was examined in a similar manner. Associations between
other exposures and serum levels of TC and TGs were
assessed in linear regression models, adjusted for age, in
men and women separately. Since the residuals in
models including TGs did not have a normal distribu-
tion, the common logarithm of TGs was used as the
dependent variable in the linear regression analyses.
Conditional logistic regression analyses were performed
first bivariately and then adjusted for the other risk factors
in multivariate analysis. Since data on menopause history
were missing in 40 % of the female participants included
in this study (Table 1), missing menopause data were in-
cluded as a separate category in this analysis.
In addition, analyses were stratified by RF status at
diagnosis or later (ever positive versus negative) and also
by time from screening to RA diagnosis (above versus
Table 1 Incident cases of rheumatoid arthritis and controls: characteristics and lipid levels, stratified by sex
All Women Men
Cases Controls Cases Controls Cases Controls
Number 290 1160 139 556 151 604
Age at inclusion 47.1 (7.1) 47.1 (7.1) 49.3 (7.4) 49.3 (7.4) 45.5 (6.2) 45.5 (6.2)
Years; mean (SD)
Time from inclusion to RA diagnosis 12 (8–18) NA 11 (7–16) NA 13 (9–19) NA
Years; median (IQR)
Age at diagnosis 59.9 (8.8; 30–81) NA 60.8 (8.4; 30–76) NA 59.1 (9.0; 40–81) NA
Years; mean (SD; range)
RF-positive at diagnosis or later 179/250 (71.6 %) NA 86/128 (67.2 %) NA 93/122 (76.2 %) NA
Current smokers at inclusion 155 (53.8 %) 486 (42.9 %) 64 (46.0 %) 197 (35.4 %) 91 (60.3 %) 289 (47.8 %)
Ever smokers at inclusion 181/260 (69.6 %) 625/1037 (60.3 %) 25/139 (61.2 %) 295/553 (53.3 %) 96/121 (79.3 %) 330/484 (68.2 %)
Blue-collar worker 146 (50.3 %) 496 (42.8 %) 67 (48.2 %) 230 (41.4 %) 79 (52.3 %) 266 (44.0 %)
White-collar worker 107 (36.9 %) 511 (44.1 %) 55 (39.6 %) 253 (45.5 %) 52 (34.4 %) 258 (42.7 %)
Early menopause (at age <46 years)* NA NA 24 % 17 % NA NA
Total cholesterol in mmol/l, mean (SD) 5.84 (1.11) 5.67 (1.04) 6.04 (1.16) 5.71 (1.10) 5.66 (1.02) 5.64 (0.98)
Triglycerides in mmol/l, 1.13 (0.78–1.57) 1.12 (0.83–1.55) 0.98 (0.76–1.48) 0.95 (0.72–1.31) 1.25 (0.90–1.70) 1.30 (0.98–1.77)
Median (IQR)
BMI in kg/m2, 24.3 (3.5) 24.7 (3.7) 24.3 (4.1) 24.3 (4.3) 24.3 (2.7) 25.0 (3.3)
mean (SD)
ESR in mm, median (IQR) 6 (4–11) 6 (4–10) 9 (5–14) 8 (5–12) 5 (3–8) 4 (3–7)
Full self-reported health 208/290 (72 %) 795/1155 (69 %) 99/139 (71 %) 364/551 (66 %) 109/151(72 %) 431/604 (71 %)
Self-reported cancer 8/260 (3 %) 28/1037 (3 %) 6/139 (4 %) 27/553 (5 %) 2/121 (2 %) 1/484 (0.2 %)
Self-reported diabetes 12/259 (5 %) 35/1036 (3 %) 9/138 (6 %) 25/562 (4 %) 3/121 (2 %) 10/484 (2 %)
Self-reported cardiovascular disease 8/260 (3 %) 27/1037 (3 %) 6/139 (4 %) 20/553 (4 %) 2/121 (2 %) 7/484 (1 %)
SD standard deviation, RA rheumatoid arthritis, IQR interquartile range, NA not applicable
*Data available from 84 cases and 334 controls
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below the median) and by age at inclusion in women:
younger than 46 years (i.e., usually pre-menopausal) ver-
sus at least 46 years. Statistical significance was set at a
P value of less than 0.05 (two-sided test).
The study was approved by the regional research ethics
committee for southern Sweden. All participants gave
their informed consent to be included in the MPMP data-
base. No informed consent was required specifically for
the present study by the regional research committee.
Results
Incident cases and controls
RA was diagnosed in a total of 290 patients (151 men
and 139 women) after inclusion in the MPMP. The me-
dian time from participation in the survey in which ex-
posure data were collected to RA diagnosis was 12 years
(range of 1–28 years), and patterns in men and women
were similar (Table 1). The mean ages at inclusion were
49.3 years in women and 45.5 years in men. There were
no substantial differences in ESR or self-reported health
between cases and controls on the basis of data collected
as part of the survey (Table 1). RA was diagnosed in six
controls (2 men and 4 women) after the index date.
Impact of lipid levels on the risk of RA-bivariate analyses
Women with a diagnosis of RA during the follow-up
had higher TC levels at baseline compared with controls:
OR 1.54 per SD; 95 % confidence interval (CI) 1.22–
1.94. By contrast, there was no significant difference in
TC levels between men who subsequently developed RA
and controls (Table 2). The slope for the estimate for the
impact of TC on RA development was significantly dif-
ferent between men and women (P < 0.001).
Furthermore, women with TC in the highest quartile
(6.5–9.7 mmol/l) had a significantly higher risk of devel-
oping RA compared with those in the second quartile
(4.9–5.6 mmol/l) (OR 3.09; 95 % CI 1.67–5.72), and
there was a similar trend for those in the third quartile
(Table 2). The risk of RA among men in the highest
quartile of TC levels was not increased compared with
those in the second quartile (OR 0.74; 95 % CI 0.42–
1.32). There was no significant impact of the quartile of
serum TG levels on the risk of RA in women or in men,
and no trend suggested a dose-dependent effect of TGs
in prediction of RA (Table 2).
Potential confounders
Smoking and blue-collar working status were predictive
of RA in both sexes (Table 2). There was a trend toward
an association between early menopause and subsequent
development of RA, although it did not reach statistical
significance in the present sample (Table 2). As we have
reported previously [28], there was a negative association
between BMI and future RA in men, whereas BMI had
Table 2 Predictors of rheumatoid arthritis: bivariate conditional logistic regression analysis, stratified by sex
Women Men
OR (95 % CI) OR (95 % CI)
Current non-smoking 1.00 (ref.) 1.00 (ref.)
Current smoking 1.61 (1.04–2.49) 1.97 (1.29–3.02)
White-collar worker 1.00 (ref.) 1.00 (ref.)
Blue-collar worker 1.45 (0.97–2.27) 1.63 (1.05–2.53)
Normal/late menopause (at age ≥46 years) 1.00 (ref.) NA
Early menopause (at age <46 years)* 1.67 (0.85–3.21) NA
BMI, per SD 1.02 (0.84-1.28) 0.72 (0.58-0.89)
Total cholesterol, per SD 1.54 (1.22–1.94) 1.03 (0.83–1.26)
Total cholesterol, per quartile Quartile 1** 1.19 (0.62–2.27) 0.84 (0.48–1.48)
Quartile 2** 1.00 (ref.) 1.00 (ref.)
Quartile 3** 1.74 (0.93–3.26) 0.92 (0.53–1.59)
Quartile 4** 3.09 (1.67–5.72) 0.74 (0.42–1.32)
Triglycerides, per quartile Quartile 1*** 0.65 (0.36–1.17) 1.54 (0.80–2.69)
Quartile 2*** 1.00 1.00
Quartile 3*** 0.62 (0.34–1.15) 0.94 (0.53–1.67)
Quartile 4** 1.23 (0.69–2.02) 0.93 (0.52–1.66)
OR odds ratio, CI confidence interval, NA not applicable, SD standard deviation, BMI body mass index
*Data available from 84 female cases and 334 controls
**Total cholesterol: quartile 1: women 2.9–4.9, men 3.1–5.0 mmol/l; quartile 2: women 4.9–5.6, men 5.0–5.6 mmol/l
Quartile 3: women 5.6–6.5, men 5.6–6.3 mmol/l; quartile 4: women 6.5–9.7, men: 6.3–9.4 mmol/l
***Triglycerides: quartile 1: women 0.30–0.73, men 0.18–0.96 mmol/l; quartile 2: women 0.73–0.95, men 0.96–1.29 mmol/l
Quartile 3: women 0.95–1.35, men 1.29–1.76 mmol/l; quartile 4: women 1.35–4.75, men: 1.76–5.32 mmol/l
Turesson et al. Arthritis Research & Therapy  (2015) 17:284 Page 4 of 9
no significant impact on the risk of RA in women
(Table 2).
Women with a history of early menopause had signifi-
cantly higher TC levels compared with those with
normal/late menopause (age-adjusted β 0.51; P < 0.001).
Current smoking was associated with higher TC in
women (age-adjusted β 0.20; P = 0.01) and there was a
similar tendency in men (age-adjusted β 0.12; P = 0.09).
Blue-collar workers, compared with white-collar workers,
tended to have lower TC levels in men (age-adjusted
β −0.09; P = 0.26). In contrast, there was no difference
in TC depending on socioeconomic status in women
(age-adjusted β 0.01 for blue-collar versus white-collar
worker status; P = 0.89). There was a positive correl-
ation between BMI and TC in women (age-adjusted β
0.02; P = 0.03) as well as in men (age-adjusted β 0.04;
P < 0.001).
TG levels were higher in current smokers compared
with non-smokers in women (P = 0.001) as well as in
men (P = 0.03). Early menopause was associated with
higher TG levels (P = 0.02). Blue-collar workers had
lower TGs compared with white-collar workers in
women (P = 0.004), whereas there was no such difference
in men (P = 0.24).
Lipids and RA-multivariate analyses
The positive association between higher TC levels and in-
creasing risk of RA in women remained statistically signifi-
cant in analyses adjusted for smoking (OR 1.47 per SD; 95
% CI 1.16–1.86) or early menopause (OR 1.45 per SD; 95
% CI 1.09–1.95) and also in a model adjusted for both co-
variates (OR 1.44 per SD; 1.13–1.83). In women, the risk
of RA was significantly elevated among those with TC in
the highest quartile, compared with the second quartile, in
analysis adjusted for smoking as well as in the model that
included both smoking and early menopause (Table 3). Re-
sults were similar in models further adjusted for socioeco-
nomic status (Table 3). The impact of TC on the risk of
RA in women remained significant in a model adjusted for
BMI in addition to smoking, early menopause, and socio-
economic status (OR 1.42; 95 % CI 1.08–1.87).
In men, there was no association between TC levels,
either as a continuous variable or per quartile, and RA
development in models adjusted for smoking alone or
smoking, socioeconomic status, and BMI (Table 4).
TG levels had no significant impact on the risk of RA in
multivariate analyses of women or men (data not shown).
Stratified analyses
In women, there was a positive association between
higher serum TC and increasing risk of RF-positive RA
(OR 1.45 per SD; 95 % CI 1.08–1.94) as well as RF-
negative RA (OR 1.85 per SD; 95 % CI 1.22–2.80). Pat-
terns were similar to the main results for the analyses by
quartile of TC (Additional file 1: Table S1). There were
no associations between TC and the risk of RA in men
in analyses stratified by RF status (Additional file 1:
Table S2).
The risk of RA diagnosis during the follow-up in-
creased significantly with higher TC in analyses of fe-
male cases investigated 1–12 years before RA diagnosis
as well as among those investigated 13–28 years before
diagnosis and their corresponding controls (Additional
file 1: Table S3). In men, patterns were similar in ana-
lyses stratified by time to RA diagnosis in the cases, and
there were no significant associations between TC and
the risk of RA (Additional file 1: Table S4).
In a limited number of individuals (27 women and 20
men), RA was diagnosed within 5 years from inclusion.
The impact of TC on the risk of RA was not substan-
tially different from that observed in the entire sample
in women (OR 1.60 per SD; 95 % CI 0.97–2.64) as well
as in men (OR 0.69 per SD; 95 % CI 0.38–1.26). Finally,
there was a significant association between TC levels
and future RA among women who were younger than
46 years at inclusion as well as among women who were
46 years or older (Additional file 1: Table S5).
Discussion
In this nested case-control study, women with a high
serum TC were at an increased risk of developing RA in
the future. By contrast, TC did not have any significant
Table 3 Impact of total cholesterol on the risk of rheumatoid arthritis in women: multivariate analyses
Adjusted for smoking Adjusted for smoking and early menopause Adjusted for smoking, early menopause
and socioeconomic status
OR (95 % CI) OR (95 % CI) OR (95 % CI)
Total cholesterol, per SD 1.47 (1.16–1.86) 1.44 (1.13–1.83) 1.42 (1.08–1.86)
Total cholesterol–quartile 1* 1.11 (0.57–2.16) 1.12 (0.58–2.18) 1.44 (0.69–3.04)
Total cholesterol–quartile 2* 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
Total cholesterol–quartile 3* 1.71 (0.90–3.24) 1.70 (0.89–3.23) 2.34 (1.13–4.81)
Total cholesterol–quartile 4* 2.72 (1.44–5.14) 2.62 (1.37–4.99) 2.79 (1.22–5.87)
OR odds ratio, CI confidence interval, SD standard deviation
*Quartile 1: 2.9–4.9 mmol/l; quartile 2: 4.9–5.6 mmol/l; quartile 3: 5.6–6.5 mmol/l; quartile 4: 6.5–9.7 mmol/l
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impact on the risk of RA in men. Serum TG levels were
not predictive of RA.
Since there was no major change in these patterns in
analyses adjusted for smoking and other potential con-
founders, it is unlikely that they are explained by such
exposures. Rates of self-reported key co-morbidities
were low and similar in cases and controls. Still, residual
confounding by other factors remains a possibility.
Data on treatment with statins and other lipid-lowering
therapy were not available in the present study. In the
1970s and 1980s, when most of the study participants
were screened, such treatment was not commonly pre-
scribed for primary prevention of CVD in Sweden. For ex-
ample, the overall utilization of lipid-lowering drugs in
1987 was estimated to be 0.6 defined daily doses per 1000
inhabitants per day in a Swedish population-based survey
[29]. Furthermore, baseline rates of self-reported CVD
and diabetes in the present sample were low, further
supporting that statin treatment at the time of inclusion
was limited. However, subsequent prescription of lipid-
lowering agents in individuals with high TC at inclusion in
the MPMP could influence the present results.
It has previously been suggested that treatment with
statins may be associated with an increased risk of devel-
oping RA [30]. This was based on a study using the
Netherlands Information Network of General Practice,
in which patients with RA were demonstrated to be
more likely to have been prescribed statin treatment
before diagnosis compared with matched controls, al-
though there was no consistent impact of treatment dur-
ation or number of defined daily doses [30]. Another
study found that, among individuals prescribed statins,
those on persistent therapy had a reduced risk of RA
compared with those with a lower proportion of days
covered by statin prescriptions [31]. Taken together, this
suggests that the relation between statin exposure and
RA development is likely to be complex.
The observation that high TC was significantly associ-
ated with increased risk of RA in women only may re-
flect underlying mechanisms that are sex-specific (e.g.,
effects related to female sex hormones). It is well estab-
lished that TC levels increase during menopause [32]
and that women with premature menopause have in-
creased TC levels compared with age-matched controls
[33]. As expected, we found that TC levels were higher in
women with a history of early menopause, and there was
a trend toward an increased risk of RA in this subset,
similar to previous reports [7, 34, 35]. However, the asso-
ciation between higher TC and RA development remained
significant in models adjusted for history of early meno-
pause. Still, we cannot rule out that hormone-related fac-
tors leading to increased TC levels explain the present
results. For example, a history of short-term breastfeeding
(≤6 months) has been associated with higher lipid levels,
reduced insulin resistance, and abdominal obesity at
follow-up 16–20 years after the last pregnancy [36], and
we [37] and others [38] have previously shown that
women who breast-feed their children for an extended
time have a reduced risk of RA. Unfortunately, data on
previous breastfeeding were not available in the studied
cohort. The fact that significant associations were seen be-
tween TC and subsequent RA development in younger
women (younger than 46 years old at inclusion), and in
women included more than 13 years before diagnosis,
suggests that long-term effects of metabolic pathways in-
fluence susceptibility to RA in women.
Obesity, which may play a differential role in men and
women with RA [9, 28], may be important in this con-
text. However, the estimated effects of TC in men and
women were similar to the main results in models ad-
justed for BMI. Differences in body fat distribution and
differences in the relation between biomarkers of inflam-
mation and lipid metabolism in women and men may
also contribute to this pattern and should be further
studied. Our results are to some extent in agreement
with those of van Halm et al., who reported higher TC
in serial samples from pre-RA cases recruited from a
population of blood donors investigated between 0.7 and
14.5 years before diagnosis [12]. However, the present
study extends these findings to a population-based
health survey of individuals from a more heterogeneous
background than most cohorts of blood donors and to
women included long before RA diagnosis. In contrast
to the study by van Halm et al. [12], we found no
Table 4 Impact of cholesterol on the risk of rheumatoid arthritis in men: multivariate analyses
Adjusted for smoking Adjusted for smoking, socioeconomic status and BMI
OR (95 % CI) OR (95 % CI)
Total cholesterol, per SD 1.01 (0.81–1.24) 1.02 (0.80–1.30)
Total cholesterol–quartile 1* 0.92 (0.52–1.62) 0.82 (0.43–1.57)
Total cholesterol–quartile 2* 1.00 (ref.) 1.00 (ref.)
Total cholesterol–quartile 3* 0.95 (0.54–1.65) 0.99 (0.53–1.85)
Total cholesterol–quartile 4* 0.75 (0.42–1.44) 0.80 (0.41–1.57)
OR odds ratio, CI confidence interval, BMI body mass index, SD standard deviation
*Quartile 1: 3.1–5.0 mmol/l; quartile 2: 5.0–5.6 mmol/l; quartile 3: 5.6–6.3 mmol/l; quartile 4: 6.3–9.4 mmol
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association between TG levels and RA development.
Potential explanations include methodological differ-
ences, such as the time of sampling (fasting in the
present study).
In a retrospective study of a population-based cohort
of patients with RA, serum TC and TGs decreased sig-
nificantly compared with matched reference subjects
during the last 5 years before RA diagnosis [39]. Data on
prescribed lipid-lowering agents did not appear to ex-
plain these changes, which may be due to early effects of
inflammation in the pre-clinical phase of RA. These ob-
servations, together with the considerable lag time from
inclusion to RA diagnosis and the low ESR levels in
most participants in the present study, suggest that our
observations of higher TC in women who later devel-
oped RA were not due to such inflammatory mecha-
nisms. Further studies of biomarker patterns in pre-RA
cases with high TC may give insights into the underlying
mechanisms and eventually be the basis for disease pre-
ventive strategies.
Current guidelines suggest monitoring of TC [40] or the
TC/HDL cholesterol ratio [41] in patients with RA and
the use of these parameters in risk score models, similar
to those recommended for the general population [42].
However, there has been a lack of consistent associations
between lipid levels and CVD co-morbidity in patients
with established RA in several studies [43–45] and a para-
doxical reverse association with TC and LDL cholesterol
in a population-based sample of patients whose RA was
diagnosed between 1988 and 2007 [17]. The present find-
ings, suggesting an extended period of hypercholesterol-
emia before disease onset in some cases, are of interest for
our understanding of atherosclerosis in the setting of RA.
Further studies should examine the relation between pre-
disease TC levels and CVD events after diagnosis.
Limitations of this study include the lack of data on
HDL and LDL cholesterol as well as on apolipoproteins.
Such data would be of particular interest, as women tend
to have higher HDL cholesterol levels than men, although
there is a decrease in HDL cholesterol and an increase in
TC and LDL cholesterol after menopause [46]. Sex-
specific effects of cholesterol fractions, as well as of lipid-
lowering treatment, should therefore be further studied.
Owing to the study design, longitudinal data on lipids
were not available. Therefore, we cannot assess the impact
of changes in TC and TGs over time on the risk of RA. In
addition, since the analyses were based on samples ob-
tained between 1974 and 1992, effects of recent secular
trends in lipid levels and related exposures in the popula-
tion would not be identified. Further studies should in-
clude data on serum lipid levels from more recent health
surveys and cases with RA onset in the last few years.
Another limitation is the lack of data on anti-
citrullinated antibody (ACPA) status after diagnosis,
which is due to the fact that for the majority of patients
the diagnosis was before routine ACPA analysis was
available. However, we did have data on RF, and RF posi-
tivity and ACPA positivity are known to have a major
overlap in patients with RA [47]. Previous studies
have indicated that predictors differ for RF/ACPA-
positive versus RF/ACPA-negative RA [48]. For ex-
ample, smoking has consistently been found to be a
significant predictor of seropositive RA but not sero-
negative RA [5, 48, 49]. The positive association be-
tween higher TC and subsequent RA development in
women was at least as strong for RF-negative RA as
for RF-positive RA, suggesting distinct underlying dis-
ease mechanisms from those related to smoking.
The strengths of this study include the prospective study
design, with exposures measured before RA diagnosis in a
standardized manner. The low number of controls whose
RA was diagnosed after the index date suggests that the
potential impact of surveillance bias in patients with high
TC and related diseases is limited. Furthermore, the in-
clusion of a relatively large sample of men who subse-
quently developed RA is a unique asset of this study. The
population-based approach, with a high participation rate
in the health survey, indicates that our cases were repre-
sentative of patients with RA in the area. On the other
hand, the cases were mainly Caucasians of Scandinavian
heritage, and the results may not apply to other ethnic
groups or other geographic settings.
Conclusions
In this prospective study, there was a positive association
between higher TC and increased long-term risk of RA
in women but not in men. The impact of TC on subse-
quent disease development in women was significant for
seropositive as well as seronegative RA. The estimates
were similar in models adjusted for relevant confounders
(i.e., smoking and early menopause). These findings sug-
gest hormone-related metabolic pathways in the early
pathogenesis of RA and may have implications for dis-
ease prevention and CVD risk management.
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